A director at Vakko Tekstil Ve Hazir Giyim Sanayi sold 397,723 shares at 105.500TRY and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the ...
A director at Deutz AG bought 6,033 shares at 5.375EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
Foresight Leverages NVIDIA Jetson Orin to Introduce Novel 360-degree 3D Perception Solution NVIDIA Jetson AGX Orin system-on-module is used to accelerate autonomous agriculture and heavy machinery projects Ness Ziona, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in automotive vision solutions, has announced a major breakthrough with the development of Dragonfly Vision™, its cutting-edge 360-degrees 3D perception solution, based on the NVIDIA Jetson AGX Orin platform, designed for power-o...
Payment of dividend Payment of dividend Regulatory release 8 May 2024, 2 p.m. The Ordinary General Meeting of Kinepolis Group NV has decided today to pay out a dividend of € 0,55 gross per share to the shareholders (€ 0,385 net after deduction of 30% withholding taxes). The dividend will be paid out as from 15 May 2024. The ex coupon date is fixed at 13 May 2024 and the record date at 14 May 2024. KINEPOLIS GROUP NV Public limited company that is making or has made a public appeal to savingsEeuwfeestlaan 20, 1020 BrusselsEnterprise Number VAT BE 0415.928.179 RLP Brussels
USARAD, Nanox’s Teleradiology Subsidiary, Awarded Accreditation from The Joint Commission Company earns Gold Seal of Approval® for Ambulatory Health Care Accreditation PETACH TIKVA, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its wholly-owned subsidiary, USARAD Holdings, Inc., a leading provider of teleradiology services, has earned The Joint Commission’s Gold Seal of Approval® for Ambulatory Health Care Accreditation for the sixth time by demonstrating continu...
First Merchants Corporation Announces Cash Dividend MUNCIE, Ind., May 08, 2024 (GLOBE NEWSWIRE) -- First Merchants Corporation declared a cash dividend on May 7, 2024 of $0.35 per share. The dividend is payable on June 21, 2024, to shareholders of record as of June 7, 2024. For purposes of broker trading, the ex-date of the cash dividend is June 6, 2024. About First Merchants Corporation: First Merchants Corporation is a financial holding company headquartered in Muncie, Indiana. The Corporation has one full-service bank charter, First Merchants Bank. The Bank also operates as First...
Small-cap specialist Hiroyuku Terada updates his forecasts for hospice facility operator CUC. He concludes that valuations remain attractive and notes that the -30% decline in the shares since the release of its new FY24 guidance on 24 April creates an opportunity to consider taking a position.
CHARLOTTE, N.C.--(BUSINESS WIRE)-- Premier, Inc. (NASDAQ: PINC) is excited to announce a strategic partnership with AstraZeneca called Uncover CKD - Care Collective aiming to identify patients with undiagnosed clinical chronic kidney disease (CKD); raise awareness of undiagnosed CKD among healthcare providers; and inform U.S. health systems that want to improve or develop and implement their strategies for CKD diagnosis, treatment and management. In the U.S., adults have CKD, and the is rising. Of these adult patients, do not know they have CKD. Total inflation-adjusted for patients with...
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company’s AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT Annual MeetingManagement webinar May 9, 2024 at 8:00 am EDT LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWS...
BioAtla to Participate in the Citizens JMP Life Sciences Conference SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024. Format: Fireside chat and scheduled one-on-one investor meetingsDate: Monday, ...
Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the first quarter ended March 31, 2024, and provide...
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD) Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected IND for PM359 recently cleared by U.S. FDA; data support advancement into Phase 1/2 clinical trial CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to deliv...
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p
LGI Homes Announces its Second Community in the Modesto Market RIVERBANK, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) today announced the opening of its second community in the Modesto, California, market, . This incredible community offers a variety of one and two-story homes and is located northeast of Modesto in the friendly town of Riverbank. “We are excited to be a part of the tremendous growth here in Riverbank. Diamond Bar East is so close to everything and offers an easy commute to the Bay Area. However, you don’t need to go anywhere because everything...
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives SYDNEY, Australia, May 08, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “Copolymer and Method for Treatment of Bacterial Infection,” for its anti-infectives, with expiry in 2035. “We thank the China National Intellectual Property Administration for their recognition of the significant potenti...
Horizon Aircraft Provides Update on Technical Flight Testing Progress ~ Continued Flight-Testing Progress Approaching Full Transition to Forward Flight of the Company’s Large-Scale Prototype eVTOL Aircraft ~ ~ Dynamic Video Footage of Most Recent Flight Test ~ ~ Continuing Detailed Design of the Full-Scale Cavorite X7 Hybrid eVTOL Aircraft, on Track for Completion and Testing in 2026 ~ TORONTO, May 08, 2024 (GLOBE NEWSWIRE) -- New Horizon Aircraft Ltd. (NASDAQ: HOVR), doing business as Horizon Aircraft (“Horizon” or the “Company”), a leading hybrid electric Vertical TakeOff and Landing...
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events BASKING RIDGE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate in the following events in May: Pharma Partnering U.S. Summit (May 14-15, 2024) Format: In-personLocation: San Diego, California Lisata Representative: Tariq Imam, VP of Business Development ...
TSS, INC. TO REPORT FIRST QUARTER 2024 RESULTS ON TUESDAY, MAY 15th, 2024 ROUND ROCK, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- TSS, Inc. (Other OTC: TSSI), a data center services company that integrates high-performance computing infrastructure and software, will report financial results for its first quarter 2024 on Tuesday May 14th, 2024. The Company will conduct a conference call at 4.30 p.m. eastern time that day. To participate on the conference call, please dial 1-888-596-4144 toll free from the U.S., or 1-646-968-2525 for international calle...
ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024 AGOURA HILLS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference. Dr. Andy Hu, Nanomedicine Manager, will be presenting: Nanomedicines: Past, Present, Future. For additional information please go to: . Dr. Hu is an experienced Biomaterial Scientist with expertise in nanomedicine, biologics, vaccines, cell, in vivo, gene therapy, drug development processes. He has great passion for innovative biotherapeutics and leading scientific ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.